LBPO.ET04 · 实验与分子治疗 · Late-Breaking

ARTS-051的表征:一种强效、选择性的Werner解旋酶抑制剂,对多种MSI-H结直肠癌模型有效

Characterization of ARTS-051, a potent and selective Werner helicase inhibitor effective against a broad range of MSI-H colorectal cancer models

编号 LB460 展板 7 时间 4/22 09:00–12:00 区域 Section 53 主讲 Christine Moomau
分会场 Late-Breaking Research: Experimental and Molecular Therapeutics 4
该海报暂无可下载的资料 AACR 官方页面

作者与单位 Authors & Affiliations

Christine Moomau1, Jiaqi Liang2, Jian Lin1, Xiaozhi Yang2, Wenheng Liang2, John Campbell1, Yipin Lu1, David Pirovich1, Tao Ji1, Lina Gu1, Fang Li1, Yaoyu Chen1, Xiang Zhai1

1Allorion Therapeutics, Natick, MA,2Anrui Bioscience, Guangzhou, China

摘要 Abstract

中文摘要
由DNA错配修复缺陷引起的微卫星不稳定性是包括结直肠癌、胃癌、子宫内膜癌和卵巢癌在内的多种癌症的特征。Werner解旋酶(WRN)是一种参与基因组维护和DNA损伤修复的RecQ解旋酶,对具有高度微卫星不稳定性(MSI-H)的癌细胞至关重要,使其成为治疗MSI-H癌症的一个有前景的靶点。在此,我们对一种新型非共价WRN抑制剂ARTS-051进行了表征,该抑制剂在多种MSI-H结直肠癌模型中均表现出强效性和选择性。在酶学实验中,ARTS-051抑制WRN的ATP酶和解旋酶活性,并对WRN相较于其亲缘关系最近的RecQ解旋酶BLM表现出超过2000倍的选择性。ARTS-051对高度敏感的MSI-H细胞系(HCT116和SW48)以及敏感性较低的MSI-H细胞系(SNU-407和RKO)的增殖均表现出优异的抑制效力。同时,ARTS-051相较于微卫星稳定(MSS)细胞系HT29表现出超过90倍的选择性。WRN C727突变会赋予对现有WRN抑制剂的耐药性,使其成为这些抑制剂的一个潜在弱点。相比之下,ARTS-051在WRN C727S和C727A突变的HCT116细胞中依然有效,其效力比处于临床阶段的WRN抑制剂HRO761高出近10倍。在包括敏感性较低的RKO模型和突变型WRN C727S HCT116模型在内的多个MSI-H细胞系来源的小鼠模型中,ARTS-051治疗可导致肿瘤消退且无显著毒性。此外,ARTS-051表现出良好的成药性,包括溶解度、渗透性和肝微粒体稳定性,以及良好的PK特征,具有低清除率和跨物种良好的口服暴露,支持有利的临床剂量预测。综上所述,这些数据表明ARTS-051是一种有前景的WRN抑制剂,具有治疗MSI-H结直肠癌的同类最佳(best-in-class)潜力。
查看英文原文 English abstract
Microsatellite instability, caused by defects in DNA mismatch repair, is a feature of many cancers including colorectal, gastric, endometrial, and ovarian. Werner helicase (WRN), a RecQ helicase involved in genome maintenance and DNA damage repair, is essential for cancer cells with high microsatellite instability (MSI-H), making it a promising target for the treatment of MSI-H cancers. Here we characterize a new non-covalent WRN inhibitor, ARTS-051, which is potent and selective across multiple MSI-H colorectal cancer models. In enzymatic assays, ARTS-051 inhibits WRN ATPase and helicase activity and displays over 2000-fold selectivity for WRN over the most closely related RecQ helicase, BLM. ARTS-051 also demonstrates excellent potency against the proliferation of both highly sensitive MSI-H cell lines (HCT116 and SW48) and less sensitive MSI-H cell lines (SNU-407 and RKO). At the same time, ARTS-051 exhibits more than 90-fold selectivity over microsatellite stable (MSS) cell line HT29. Mutation of WRN C727 confers resistance to existing WRN inhibitors, making it a potential vulnerability of these inhibitors. In contrast, ARTS-051 is effective in WRN C727S and C727A mutant HCT116 cells, outperforming the clinical stage WRN inhibitor HRO761 by nearly 10-fold. In multiple MSI-H cell-line derived mouse models including the less sensitive RKO and mutant WRN C727S HCT116 models, treatment with ARTS-051 leads to tumor regression without significant toxicity. Additionally, ARTS-051 displays good drug-like properties including solubility, permeability, and liver microsome stability, as well as a positive PK profile with low clearance and good oral exposure across species, supporting favorable clinical dose projections. Taken together, these data show that ARTS-051 is a promising WRN inhibitor with best-in-class potential to treat MSI-H colorectal cancers.
利益披露 Disclosure
C. Moomau, None.. J. Liang, None.. J. Lin, None.. X. Yang, None.. W. Liang, None.. J. Campbell, None.. Y. Lu, None.. D. Pirovich, None.. T. Ji, None.. L. Gu, None.. F. Li, None.. Y. Chen, None.. X. Zhai, None.

← 返回 AACR 2026 检索